Rallybio Raises $250M to Transform Treatment for Severe and Rare Diseases

Rallybio is thrilled to announce a major milestone in our journey towards transforming patient care—raising $250,000,000 in new funding to accelerate our mission of turning science’s toughest obstacles into breakthroughs in healthcare. As a clinical-stage biotechnology company headquartered in New Haven, Connecticut, Rallybio is committed to developing and commercializing life-transforming therapies for patients with severe and rare diseases. Our state-of-the-art clinical programs, including RLYB212—an innovative anti-HPA-1a antibody designed for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT)—and RLYB116, an inhibitor of complement component 5 (C5) with expansive potential to treat disorders resulting from complement dysregulation, sit at the forefront of our scientific dedication. This recent funding injection will empower us to propel these critical development programs forward, enhance our broad pipeline of promising product candidates in maternal fetal health, hematology, and metabolic disorders, and bolster our efforts in preclinical research. More than just financial support, this investment is a powerful endorsement of our unique vision to tackle unmet medical needs with bold, innovative strategies. By rallying the brightest minds, forging strategic partnerships, and harnessing cutting-edge science, we are positioned to navigate the complexities of drug development and bring truly transformational solutions to patients around the world. This funding not only strengthens our financial foundation but also accelerates our mission-driven journey to redefine what is possible in clinical science. We remain dedicated to transparency, collaboration, and excellence as we take these pivotal next steps in our quest for scientific discovery and improved patient outcomes.